$TSBX News
Last published 1y ago
- 1y agoTSBXXOMAXOMAOXOMAPXOMA Royalty Announces Closing of Tender Offer for Turnstone BiologicsGlobeNewswire- Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty" or the "Company"), a
- 1y agoTSBXXOMAXOMAOXOMAPTurnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value RightGlobeNewswireEMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced
- 1y agoTSBXTurnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate HighlightsGlobeNewswireSAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat
- 1y agoTSBXTurnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireSAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to
- 1y agoTSBXTurnstone Biologics Announces Plans to Explore Strategic AlternativesGlobeNewswireSAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced that it has completed an assessment of its business and operations, including the
- 1y agoTSBXTurnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business HighlightsGlobeNewswireSAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure
- 2y agoTSBXTurnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewswireTurnstone's next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinical advancement of
- 2y agoTSBXTurnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial RunwayGlobeNewswireRealigning resources to focus on clinical advancement of Selected TIL therapyReducing employee headcount by approximately 60%Streamlining operations with cash runway expected to extend into 2Q 2026 SAN DIEGO, Oct.
- 2y agoTSBXTurnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business HighlightsGlobeNewswireAnnounced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operations into 3Q 2025
- 2y agoTSBXTurnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal CancerGlobeNewswireOverall response rate ("ORR") of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC Complete response achieved in heavily pre-treated late
- 2y agoTSBXTurnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business HighlightsGlobeNewswireSAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients
- 2y agoTSBXTurnstone Biologics to Present at the 2024 Bank of America Securities Health Care ConferenceGlobeNewswireSAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients
- 2y agoANNXARWRPTGXTSBXTurnstone Biologics Appoints William Waddill to its Board of DirectorsGlobeNewswireSAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure
- 2y agoTSBXTurnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business HighlightsGlobeNewswireLead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone's novel Selected TIL programs for solid tumors presented at SITC 2023
- 2y agoTSBXTurnstone Biologics to Participate in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure
- 2y agoTSBXTurnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.GlobeNewswireSAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure
- 2y agoTSBXTurnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare ConferenceGlobeNewswireSAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid
- 3y agoTSBXTurnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business HighlightsGlobeNewswire– Promising preclinical data showcasing Turnstone's novel Selected TIL programs for solid tumors presented at SITC 2023 – – Lead program, TIDAL-01, advancing and on track in two Phase 1 trials with initial clinical
- 3y agoTSBXTurnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewswirePresentations showcase Turnstone's novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Data further supports the continued clinical
- 3y agoTSBXTurnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. WeberGlobeNewswireSAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by
- 3y agoTSBXTurnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingGlobeNewswireSAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by
- 3y agoTSBXTurnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireSuccessfully closed upsized IPO, raising $88 million in gross proceeds to continue advancing pipeline of Selected TIL Therapy programsCash position expected to fund operations into second quarter of 2025Two Phase 1
- 3y agoTSBXTurnstone Biologics Corp. Announces Pricing of Upsized Initial Public OfferingGlobeNewswireSAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by